The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial

Abstract

Background: Low-dose naltrexone (LDN) may promote psychological well-being as well as generalized health especially in autoimmune disorders. The objective of this study is to assess the effect of LDN on the Quality of Life (QoL) of patients with relapsing—remitting and secondary progressive multiple sclerosis (MS) using the scales and composite scores of the MSQoL-54 questionnaire.

Methods: A 17-week randomized, double-blind, placebo-controlled, parallel-group, crossover-design clinical trial was conducted in two universities. A total of 96 adult patients aged between 15 and 65 years with relapsing—remitting (RR) or secondary progressive (SP) clinically definite MS with disease duration longer than 6 months enrolled into the study. The primary outcome of the study was comparison of the scores of physical and mental health by conducting independent t-test of the results obtained in the middle and at the end of study between the two groups.

Results: Variables including presence of pain, energy, emotional well-being, social, cognitive, and sexual functions, role limitation due to physical and emotional problems, health distress, and overall QoL did not show any meaningful statistically difference between the two groups. Factor analysis revealed that health perception scores were statistically different between the groups before starting, in the middle, and at the end of the study.

Conclusion: The study clearly illustrates that LDN is a relatively safe therapeutic option in RRMS and SPMS but its efficacy is under question and probably a long duration trial is needed in the future.

Keywords

efficacy low-dose naltrexone multiple sclerosis MSQoL-54

Get full access to this article

View all access options for this article.

References

Brown N. , Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 2009; 72: 333-337.

Weerts EM , Kim YK , Wand GS , et al. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology 2008; 33: 653-665.

Gharagozlou P. , Hashemi E. , DeLorey TM , Clark JD , Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol 2006 ; 6: 3.

Zagon IS , Rahn KA , Turel AP , McLaughlin PJ Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) 2009; 234: 1383-1392.

Mannelli P. , Patkar AA , Peindl K. , Murray HW , Wu LT , Hubbard R. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. J Clin Psychopharmacol 2007; 27: 468-474.

Webster LR , Butera PG , Moran LV , Wu N. , Burns LH , Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006; 7: 937-946.

Crabtree BL Review of naltrexone, a long-acting opiate antagonist. Clin Pharm 1984; 3: 273-280.

Gironi M. , Martinelli-Boneschi F. , Sacerdote P. , et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008; 14: 1076-1083.

Rajashekara V. , Patel CN , Patel K. , Purohit V. , Yoburn BC Chronic opioid antagonist treatment dose-dependently regulates mu-opioid receptors and trafficking proteins in vivo. Pharmacol Biochem Behav 2003; 75: 909-913.

10.

Yoburn BC , Goodman RR , Cohen AH , Pasternak GW , Inturrisi CE Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment. Life Sci 1985; 36: 2325-2332.

11.

Panerai AE , Vecchiet J. , Panzeri P. , et al. Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. Clin J Pain 2002; 18: 270-273.

12.

Wiedermann CJ , Sacerdote P. , Propst A. , et al. Decreased beta-endorphin content in peripheral blood mononuclear leukocytes from patients with Crohn’s disease . Brain Behav Immun 1994; 8: 261-269.

13.

Gironi M. , Furlan R. , Rovaris M. , et al. Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74: 495-497.

14.

Vickrey BG , Hays RD , Harooni R. , Myers LW , Ellison GW A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206.

15.

McDonald WI , Compston A. , Edan G. , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

16.

Polman CH , Reingold SC , Edan G. , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005; 58: 840-846.

17.

Ghaem H. , Haghighi AB , Jafari P. , Nikseresht AR Validity and reliability of the Persian version of the multiple sclerosis quality of life questionnaire. Neurol India 2007; 55: 369-375.

18.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.

19.

Kurtzke JF Disability rating scales in multiple sclerosis. Ann N Y Acad Sci 1984; 436: 347-360.

20.

Miltenburger C. , Kobelt G. Quality of life and cost of multiple sclerosis . Clin Neurol Neurosur 2002; 104: 272-275.

21.

Nortvedt MW , Riise T. , Myhr KM , Nyland HI Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology 1999; 53: 1098-1103.

22.

Aronson KJ Quality of life among persons with multiple sclerosis and their caregivers . Neurology 1997; 48: 74-80.

23.

Rothwell PM Quality of life in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 65: 433.

24.

Agrawal YP Low dose naltrexone therapy in multiple sclerosis. Med Hypoth 2005; 64: 721-724.

25.

Gironi M. , Martinelli V. , Brambilla E. , et al. Beta-endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis: effects of treatment with interferon beta. Arch Neurol 2000; 57: 1178-1181.

26.

Baker D. , Pryce G. , Croxford JL , et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87.

27.

Zajicek J. , Fox P. , Sanders H. , et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-1526.

28.

Benjamins MR , Finlayson M. Using religious services to improve health: findings from a sample of middle-aged and older adults with multiple sclerosis . J Aging Health 2007; 19: 537-553.

29.

Büssing A. , Ostermann T. , Koenig HG Relevance of religion and spirituality in German patients with chronic diseases. Int J Psychiatry Med 2007; 37: 39-57.